FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386304317> ?p ?o ?g. }

• W4386304317 abstract "Androgen receptor (AR) plays a vital role in the development and progression of prostate cancer from the primary stage to the usually lethal stage known as castration-resistant prostate cancer (CRPC). Constitutively active AR splice variants (AR-Vs) lacking the ligand-binding domain are partially responsible for the abnormal activation of AR and may be involved in resistance to AR-targeting drugs occurring in CRPC. There is increasing consensus on the potential of drugs targeting protein–protein interactions. Our lab has recently identified transmembrane 4 superfamily 3 (TM4SF3) as a critical interacting partner for AR and AR-V7 and mapped the minimal interaction regions. Thus, we hypothesized that these interaction domains can be used to design peptides that can disrupt the AR/TM4SF3 interaction and kill prostate cancer cells. Peptides TA1 and AT1 were designed based on the TM3SF3 or AR interaction domain, respectively. TA1 or AT1 was able to decrease AR/TM4SF3 protein interaction and protein stability. Peptide TA1 reduced the recruitment of AR and TM4SF3 to promoters of androgen-regulated genes and subsequent activation of these AR target genes. Peptides TA1 and AT1 were strongly cytotoxic to prostate cancer cells that express AR and/or AR-V7. Peptide TA1 inhibited the growth and induced apoptosis of both enzalutamide-sensitive and importantly enzalutamide-resistant prostate cancer cells. TA1 also blocked the migration and malignant transformation of prostate cancer cells. Our data clearly demonstrate that using peptides to target the important interaction AR has with TM4SF3 provides a novel method to kill enzalutamide-resistant prostate cancer cells that can potentially lead to new more effective therapy for CRPC." @default.
• W4386304317 created "2023-09-01" @default.
• W4386304317 creator A5020260630 @default.
• W4386304317 creator A5034451266 @default.
• W4386304317 creator A5050020096 @default.
• W4386304317 creator A5070013635 @default.
• W4386304317 creator A5084174557 @default.
• W4386304317 date "2023-01-01" @default.
• W4386304317 modified "2023-10-14" @default.
• W4386304317 title "Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation" @default.
• W4386304317 cites W1135170528 @default.
• W4386304317 cites W1495912963 @default.
• W4386304317 cites W1740737174 @default.
• W4386304317 cites W1917299631 @default.
• W4386304317 cites W1956445706 @default.
• W4386304317 cites W1970169718 @default.
• W4386304317 cites W1975609403 @default.
• W4386304317 cites W1981542504 @default.
• W4386304317 cites W1983680531 @default.
• W4386304317 cites W1990287298 @default.
• W4386304317 cites W1992411393 @default.
• W4386304317 cites W1996956937 @default.
• W4386304317 cites W2008498145 @default.
• W4386304317 cites W2008549629 @default.
• W4386304317 cites W2012129117 @default.
• W4386304317 cites W2016771357 @default.
• W4386304317 cites W2059134151 @default.
• W4386304317 cites W2068063264 @default.
• W4386304317 cites W2072301658 @default.
• W4386304317 cites W2073097174 @default.
• W4386304317 cites W2095919110 @default.
• W4386304317 cites W2101285353 @default.
• W4386304317 cites W2119504728 @default.
• W4386304317 cites W2125069527 @default.
• W4386304317 cites W2129509993 @default.
• W4386304317 cites W2149131962 @default.
• W4386304317 cites W2171450779 @default.
• W4386304317 cites W2181253247 @default.
• W4386304317 cites W2190784797 @default.
• W4386304317 cites W2229137974 @default.
• W4386304317 cites W2556148213 @default.
• W4386304317 cites W2568836017 @default.
• W4386304317 cites W2582372140 @default.
• W4386304317 cites W2589295155 @default.
• W4386304317 cites W2623921962 @default.
• W4386304317 cites W2804747524 @default.
• W4386304317 cites W2953836551 @default.
• W4386304317 cites W2989569138 @default.
• W4386304317 cites W2996266725 @default.
• W4386304317 cites W2999417355 @default.
• W4386304317 cites W3010357846 @default.
• W4386304317 cites W3015471106 @default.
• W4386304317 cites W3024799748 @default.
• W4386304317 cites W4360600260 @default.
• W4386304317 doi "https://doi.org/10.1530/eo-23-0010" @default.
• W4386304317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37822366" @default.
• W4386304317 hasPublicationYear "2023" @default.
• W4386304317 type Work @default.
• W4386304317 citedByCount "0" @default.
• W4386304317 crossrefType "journal-article" @default.
• W4386304317 hasAuthorship W4386304317A5020260630 @default.
• W4386304317 hasAuthorship W4386304317A5034451266 @default.
• W4386304317 hasAuthorship W4386304317A5050020096 @default.
• W4386304317 hasAuthorship W4386304317A5070013635 @default.
• W4386304317 hasAuthorship W4386304317A5084174557 @default.
• W4386304317 hasBestOaLocation W43863043171 @default.
• W4386304317 hasConcept C121608353 @default.
• W4386304317 hasConcept C126322002 @default.
• W4386304317 hasConcept C185592680 @default.
• W4386304317 hasConcept C2776551883 @default.
• W4386304317 hasConcept C2780192828 @default.
• W4386304317 hasConcept C502942594 @default.
• W4386304317 hasConcept C61367390 @default.
• W4386304317 hasConcept C71924100 @default.
• W4386304317 hasConcept C86803240 @default.
• W4386304317 hasConcept C95444343 @default.
• W4386304317 hasConcept C96232424 @default.
• W4386304317 hasConceptScore W4386304317C121608353 @default.
• W4386304317 hasConceptScore W4386304317C126322002 @default.
• W4386304317 hasConceptScore W4386304317C185592680 @default.
• W4386304317 hasConceptScore W4386304317C2776551883 @default.
• W4386304317 hasConceptScore W4386304317C2780192828 @default.
• W4386304317 hasConceptScore W4386304317C502942594 @default.
• W4386304317 hasConceptScore W4386304317C61367390 @default.
• W4386304317 hasConceptScore W4386304317C71924100 @default.
• W4386304317 hasConceptScore W4386304317C86803240 @default.
• W4386304317 hasConceptScore W4386304317C95444343 @default.
• W4386304317 hasConceptScore W4386304317C96232424 @default.
• W4386304317 hasIssue "1" @default.
• W4386304317 hasLocation W43863043171 @default.
• W4386304317 hasLocation W43863043172 @default.
• W4386304317 hasOpenAccess W4386304317 @default.
• W4386304317 hasPrimaryLocation W43863043171 @default.
• W4386304317 hasRelatedWork W1984464970 @default.
• W4386304317 hasRelatedWork W2180958531 @default.
• W4386304317 hasRelatedWork W2479406918 @default.
• W4386304317 hasRelatedWork W2593283143 @default.
• W4386304317 hasRelatedWork W2681186693 @default.
• W4386304317 hasRelatedWork W2773216890 @default.
• W4386304317 hasRelatedWork W2931472946 @default.

• next